Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
The use of novel glucose lowering therapies to reduce cardiorenal risk in kidney transplant recipients
FY 2023-24
Summary
Chronic kidney disease is a devastating condition leading to kidney failure. Individuals with kidney failure suffer from increased hospitalization and death. Kidney failure also results in increased societal costs related to healthcare spending and disability. Kidney transplantation is the best treatment option for kidney replacement therapy. However, kidney transplant recipients have an increased risk of death due to heart disease and graft failure, where the transplanted kidney no longer works and dialysis or another kidney transplant is required. The risk of death is higher in the presence of diabetes, which is common in transplanted individuals. Currently, effective treatments which protect heart and kidney function following transplant are lacking. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) are two new therapies for diabetes management which have shown significant benefits in protecting heart and kidney function in non-transplanted individuals. Preliminary evidence suggests these benefits extend to the transplant population. Our study will investigate the protective effects of SGLT2i or GLP1RA in kidney transplant recipients. We will review the medical records of transplanted patients and compare kidney and heart function in patients who have used SGLT2i or GLP1RA versus patients who have not used either therapy. Our results will add to the emerging evidence which supports the use of these therapies in the transplant population. This may encourage transplant nephrologists to incorporate these therapies in the care of kidney transplant recipients, possibly leading to improved health outcomes and reduced healthcare costs. Study findings will also be used to design and implement new studies in this field.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506495
Name
Mohsen Mai H
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The use of novel glucose lowering therapies to reduce cardiorenal risk in kidney transplant recipients
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cardiac Outcomes; Glucagon-Like Peptide-1 Receptor Agonists; Kidney Transplant Recipients; Renal Outcomes; Sodium-Glucose Cotransporter-2 Inhibitors
Abstract
Chronic kidney disease is a devastating condition leading to kidney failure. Individuals with kidney failure suffer from increased hospitalization and death. Kidney failure also results in increased societal costs related to healthcare spending and disability. Kidney transplantation is the best treatment option for kidney replacement therapy. However, kidney transplant recipients have an increased risk of death due to heart disease and graft failure, where the transplanted kidney no longer works and dialysis or another kidney transplant is required. The risk of death is higher in the presence of diabetes, which is common in transplanted individuals. Currently, effective treatments which protect heart and kidney function following transplant are lacking. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) are two new therapies for diabetes management which have shown significant benefits in protecting heart and kidney function in non-transplanted individuals. Preliminary evidence suggests these benefits extend to the transplant population. Our study will investigate the protective effects of SGLT2i or GLP1RA in kidney transplant recipients. We will review the medical records of transplanted patients and compare kidney and heart function in patients who have used SGLT2i or GLP1RA versus patients who have not used either therapy. Our results will add to the emerging evidence which supports the use of these therapies in the transplant population. This may encourage transplant nephrologists to incorporate these therapies in the care of kidney transplant recipients, possibly leading to improved health outcomes and reduced healthcare costs. Study findings will also be used to design and implement new studies in this field.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mohsen, Mai H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~